That's something most shareholders can agree on. It will bring growth beyond the mid teens guided by management. I was initially optimistic about it many years ago but I have tampered my hopes down after reading about many failed trial in the cardiovascular space. I'm sure the SP would take a hit if it failed but if successful the uplift in SP would be a lot more than the hit imo.
$300 by calendar year end, page-14
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$308.05 |
Change
2.510(0.82%) |
Mkt cap ! $148.8B | |||
| Open | High | Low | Value | Volume |
| $307.94 | $309.48 | $306.35 | $254.8M | 840.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 268 | $307.92 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $308.23 | 139 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |